**Supplementary table 1: Different dosing schemes and median IFX trough levels post-induction and at week 52.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Induction scheme** | **Interval (wk.)** | **Dose (mg/kg)** | **N** | **Post-induction IFX trough level [IQR]** |
| Normal induction scheme | 0- 2- 6- 14 | 5- 5- 5 | 21 | 3.2 µg/mL [1.8-5.7] |
| Expedited induction scheme | 0- 2- 6- 12 | 5- 5- 5 | 7 | 3.0 µg/mL [1.5-12.0] |
| Intensified induction scheme | 0- 1- 4 | 5- 5- 5 | 2 | 3.4 µg/mL [2.6-12.0] |
| 0- 2- 4 | 5- 5- 10 | 2 |
| 0- 2- 6 | 5- 5- 10 | 3 |
| **Maintenance scheme** using pro-active TDM (see Suppl Digital Content 1) | **Standardized IFX dose [IQR]** expressed as a 8-week interval | | N | **IFX trough level [IQR] at week 52** |
| 8.0 mg/kg [6.4-10.0] | | 35 | 5.1 µg/mL [3.6-7.1] |

**Footnotes:** Standardized infliximab dose are expressed as 8-week interval to simplify this recording. Thus, if the administrated infliximab dose of the patient was for example 7.5 mg/kg with an interval of 6 weeks, the standardized dose is 10 mg/kg/8 weeks. IFX: infliximab, IQR: interquartile range, n: number; TDM: therapeutic drug monitoring, wk.: weeks.